{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114983","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.667043+00:00","generated_at":"2026-06-08T17:00:03.024058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia Q3 net loss $15.8M; YUTREPIA PH-ILD PDUFA Jan 24, 2024","bullets":["Net loss $15.8M ($0.24/sh) vs $9.1M ($0.14/sh) in Q3 2022; cash $76.2M vs $93.3M at year-end.","Revenue $3.7M (+15% YoY) from Sandoz treprostinil injection promotion agreement.","R&D spend up 65% to $7.4M on YUTREPIA pre-launch; G&A up 57% to $10.6M on litigation and commercial prep.","PDUFA date for PH-ILD label expansion Jan 24, 2024; final approval delayed to Mar 31, 2024 due to Tyvaso exclusivity.","Oral arguments in '793 patent appeal set for Dec 4, 2023; CAFC ruling could enable final YUTREPIA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114983","json":"https://secwatch.observer/filing/0001104659-23-114983.json","markdown":"https://secwatch.observer/filing/0001104659-23-114983.md","text":"https://secwatch.observer/filing/0001104659-23-114983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/tm2329950d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:00:03.024058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1310d8cc950206c1e62f97e7dbf5cdfad2fbbf2f","claim":"Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.","evidence_excerpt":"for PAH and PH-ILD. Third Quarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. Revenue related primarily to the promotion agreement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$3.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}